Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China

DOI record: { "DOI": "10.3390/microorganisms11071859", "ISSN": [ "2076-2607" ], "URL": "http://dx.doi.org/10.3390/microorganisms11071859", "abstract": "<jats:p>Background: The sixty-day effects of initial composite interventions for the treatment of severely and critically ill patients with COVID-19 are not fully assessed. Methods: Using a Bayesian piecewise exponential model, we analyzed the 60-day mortality, health-related quality of life (HRQoL), and disability in 1082 severely and critically ill patients with COVID-19 between 8 December 2022 and 9 February 2023 in Shanghai, China. The final 60-day follow-up was completed on 10 April 2023. Results: Among 1082 patients (mean age, 78.0 years, 421 [38.9%] women), 139 patients (12.9%) died within 60 days. Azvudine had a 99.8% probability of improving 2-month survival (adjusted HR, 0.44 [95% credible interval, 0.24–0.79]), and Paxlovid had a 91.9% probability of improving 2-month survival (adjusted HR, 0.71 [95% credible interval, 0.44–1.14]) compared with the control. IL-6 receptor antagonist, baricitinib and a-thymosin each had a high probability of benefit (99.5%, 99.4%, and 97.5%, respectively) compared to their controls, while the probability of trail-defined statistical futility (HR &gt; 0.83) was high for therapeutic anticoagulation (99.8%; HR, 1.64 [95% CrI, 1.06–2.50]) and glucocorticoid (91.4%; HR, 1.20 [95% CrI, 0.71–2.16]). Paxlovid, Azvudine, and therapeutic anticoagulation showed a significant reduction in disability (p &lt; 0.05) Conclusions: Among severely and critically ill patients with COVID-19 who received 1 or more therapeutic interventions, treatment with Azvudine had a high probability of improved 60-day mortality compared with the control, indicating its potential in a resource-limited scenario. Treatment with an IL-6 receptor antagonist, baricitinib, and a-thymosin also had high probabilities of benefit in improving 2-month survival, among which a-thymosin could improve HRQoL. Treatment with Paxlovid, Azvudine, and therapeutic anticoagulation could significantly reduce disability at day 60.</jats:p>", "alternative-id": [ "microorganisms11071859" ], "author": [ { "ORCID": "http://orcid.org/0000-0001-6345-5350", "affiliation": [ { "name": "Department of Immunology and Rheumatology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201899, China" }, { "name": "Tulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA" } ], "authenticated-orcid": false, "family": "Shao", "given": "Jiasheng", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-0814-0548", "affiliation": [ { "name": "Tulane National Primate Research Center, Tulane University School of Medicine, 18703 Three Rivers Road, Covington, LA 70433, USA" }, { "name": "Genomics, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität, 01307 Dresden, Germany" } ], "authenticated-orcid": false, "family": "Fan", "given": "Rong", "sequence": "additional" }, { "affiliation": [ { "name": "Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China" } ], "family": "Guo", "given": "Chengnan", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Urology, Renji Hospital, Shanghai JiaoTong University, Shanghai 200127, China" } ], "family": "Huang", "given": "Xuyuan", "sequence": "additional" }, { "affiliation": [ { "name": "Department of General Surgery, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201899, China" } ], "family": "Guo", "given": "Runsheng", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Infectious Disease, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China" } ], "family": "Zhang", "given": "Fengdi", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Respiratory Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201899, China" } ], "family": "Hu", "given": "Jianrong", "sequence": "additional" }, { "affiliation": [ { "name": "Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China" } ], "family": "Huang", "given": "Gang", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Ren Ji Hospital, Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China" } ], "family": "Cao", "given": "Liou", "sequence": "additional" } ], "container-title": "Microorganisms", "container-title-short": "Microorganisms", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2023, 7, 24 ] ], "date-time": "2023-07-24T05:08:11Z", "timestamp": 1690175291000 }, "deposited": { "date-parts": [ [ 2023, 7, 24 ] ], "date-time": "2023-07-24T06:24:59Z", "timestamp": 1690179899000 }, "funder": [ { "DOI": "10.13039/501100001809", "award": [ "82127807" ], "doi-asserted-by": "publisher", "name": "National Natural Science Foundation of China" }, { "award": [ "18DZ2260400" ], "name": "Shanghai Key Laboratory of Molecular Imaging" }, { "award": [ "20MC2020004" ], "name": "Shanghai University of Medicine and Health Sciences Clinical Research Centre for Metabolic Vascular Diseases Project" }, { "award": [ "JDKW-2021-0022" ], "name": "Science and Technology Commission of Jiading District" } ], "indexed": { "date-parts": [ [ 2024, 2, 15 ] ], "date-time": "2024-02-15T12:02:09Z", "timestamp": 1707998529374 }, "is-referenced-by-count": 1, "issue": "7", "issued": { "date-parts": [ [ 2023, 7, 23 ] ] }, "journal-issue": { "issue": "7", "published-online": { "date-parts": [ [ 2023, 7 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 7, 23 ] ], "date-time": "2023-07-23T00:00:00Z", "timestamp": 1690070400000 } } ], "link": [ { "URL": "https://www.mdpi.com/2076-2607/11/7/1859/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "1859", "prefix": "10.3390", "published": { "date-parts": [ [ 2023, 7, 23 ] ] }, "published-online": { "date-parts": [ [ 2023, 7, 23 ] ] }, "publisher": "MDPI AG", "reference": [ { "DOI": "10.1111/eci.13956", "article-title": "Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy", "author": "Ioannidis", "doi-asserted-by": "crossref", "first-page": "e13956", "journal-title": "Eur. J. Clin. Investig.", "key": "ref_1", "volume": "53", "year": "2023" }, { "DOI": "10.1136/bmj.p2", "article-title": "COVID-19: China stops counting cases as models predict a million or more deaths", "author": "Dyer", "doi-asserted-by": "crossref", "first-page": "2", "journal-title": "BMJ", "key": "ref_2", "volume": "380", "year": "2023" }, { "DOI": "10.1016/j.jinf.2022.08.001", "article-title": "Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "e27", "journal-title": "J. Infect.", "key": "ref_3", "volume": "86", "year": "2023" }, { "DOI": "10.1101/2022.07.03.22277169", "doi-asserted-by": "crossref", "key": "ref_4", "unstructured": "Shao, J., Fan, R., Hu, J., Zhang, T., Lee, C., Huang, X., Wang, F., Liang, H., Jin, Y., and Jiang, Y. (2022). Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China. Vaccines, 10." }, { "DOI": "10.1016/S0140-6736(21)01755-4", "article-title": "1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study", "author": "Huang", "doi-asserted-by": "crossref", "first-page": "747", "journal-title": "Lancet", "key": "ref_5", "volume": "398", "year": "2021" }, { "DOI": "10.1016/S2213-2600(22)00126-6", "article-title": "Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study", "author": "Huang", "doi-asserted-by": "crossref", "first-page": "863", "journal-title": "Lancet Respir. Med.", "key": "ref_6", "volume": "10", "year": "2022" }, { "DOI": "10.1016/j.jinf.2020.03.037", "article-title": "The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19", "author": "Ye", "doi-asserted-by": "crossref", "first-page": "607", "journal-title": "J. Infect.", "key": "ref_7", "volume": "80", "year": "2020" }, { "DOI": "10.1016/j.jinf.2022.12.027", "article-title": "Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study", "author": "Cilloniz", "doi-asserted-by": "crossref", "first-page": "256", "journal-title": "J. Infect.", "key": "ref_8", "volume": "86", "year": "2023" }, { "DOI": "10.1001/jama.2022.23257", "article-title": "Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial", "author": "Florescu", "doi-asserted-by": "crossref", "first-page": "39", "journal-title": "JAMA", "key": "ref_9", "volume": "329", "year": "2023" }, { "DOI": "10.1001/jama.2021.18178", "article-title": "Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial", "author": "Abdelhady", "doi-asserted-by": "crossref", "first-page": "1690", "journal-title": "JAMA", "key": "ref_10", "volume": "326", "year": "2021" }, { "DOI": "10.1056/NEJMoa2103417", "article-title": "Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19", "author": "Goligher", "doi-asserted-by": "crossref", "first-page": "777", "journal-title": "N. Engl. J. Med.", "key": "ref_11", "volume": "385", "year": "2021" }, { "DOI": "10.1001/jama.2022.2910", "article-title": "Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial", "author": "Bradbury", "doi-asserted-by": "crossref", "first-page": "1247", "journal-title": "JAMA", "key": "ref_12", "volume": "327", "year": "2022" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in Hospitalized Patients with COVID-19", "author": "Group", "doi-asserted-by": "crossref", "first-page": "693", "journal-title": "N. Engl. J. Med.", "key": "ref_13", "volume": "384", "year": "2021" }, { "DOI": "10.1016/j.jinf.2023.02.029", "article-title": "Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase", "author": "Wan", "doi-asserted-by": "crossref", "first-page": "622", "journal-title": "J. Infect.", "key": "ref_14", "volume": "86", "year": "2023" }, { "key": "ref_15", "unstructured": "National Health Commission of the People’s Republic of China (2023, July 18). Diagnosis and Treatment Plan for COVID-19 (Trial Version 10). in Chinese, Available online: http://www.nhc.gov.cn/xcs/zhengcwj/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml." }, { "DOI": "10.1016/S2213-2600(22)00006-6", "article-title": "Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial", "author": "Ely", "doi-asserted-by": "crossref", "first-page": "327", "journal-title": "Lancet Respir. Med.", "key": "ref_16", "volume": "10", "year": "2022" }, { "key": "ref_17", "unstructured": "Üstün, T.B., Kostanjesek, N., Chatterji, S., and Rehm, J. (2010). Measuring Health and Disability, Manual for WHO Disability Assessment Schedule, WHODAS 2.0, WHO." }, { "DOI": "10.1016/j.jval.2016.11.016", "article-title": "Estimating an EQ-5D-5L Value Set for China", "author": "Luo", "doi-asserted-by": "crossref", "first-page": "662", "journal-title": "Value Health", "key": "ref_18", "volume": "20", "year": "2017" }, { "DOI": "10.1080/22221751.2021.2011619", "article-title": "Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: A prospective cohort study", "doi-asserted-by": "crossref", "first-page": "50", "journal-title": "Emerg. Microbes. Infect.", "key": "ref_19", "volume": "11", "year": "2022" }, { "DOI": "10.1186/s13643-021-01838-8", "article-title": "Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: A protocol of a META-epidemiological study", "author": "Varela", "doi-asserted-by": "crossref", "first-page": "289", "journal-title": "Syst. Rev.", "key": "ref_20", "volume": "10", "year": "2021" }, { "DOI": "10.1016/j.lanwpc.2023.100694", "article-title": "Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: A multicenter randomized controlled study", "author": "Liu", "doi-asserted-by": "crossref", "first-page": "100694", "journal-title": "Lancet Reg. Health West Pac.", "key": "ref_21", "volume": "33", "year": "2023" }, { "DOI": "10.1038/s41392-021-00835-6", "article-title": "Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "414", "journal-title": "Signal. Transduct. Target Ther.", "key": "ref_22", "volume": "6", "year": "2021" }, { "article-title": "Expert consensus on treatment of severe COVID-19 caused by Omicron variants", "first-page": "101", "journal-title": "Zhonghua Jie He He Hu Xi Za Zhi", "key": "ref_23", "volume": "46", "year": "2023" }, { "DOI": "10.1016/j.jinf.2020.04.012", "article-title": "Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China", "author": "Xu", "doi-asserted-by": "crossref", "first-page": "e51", "journal-title": "J. Infect.", "key": "ref_24", "volume": "81", "year": "2020" }, { "DOI": "10.1093/cid/ciaa630", "article-title": "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells", "author": "Liu", "doi-asserted-by": "crossref", "first-page": "2150", "journal-title": "Clin. Infect. Dis.", "key": "ref_25", "volume": "71", "year": "2020" }, { "DOI": "10.1016/j.intimp.2023.109949", "article-title": "COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections", "author": "Bellet", "doi-asserted-by": "crossref", "first-page": "109949", "journal-title": "Int. Immunopharmacol.", "key": "ref_26", "volume": "117", "year": "2023" }, { "DOI": "10.3389/fimmu.2023.1116738", "article-title": "Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis", "author": "Liu", "doi-asserted-by": "crossref", "first-page": "1116738", "journal-title": "Front. Immunol.", "key": "ref_27", "volume": "14", "year": "2023" }, { "DOI": "10.1186/s40001-022-00637-8", "article-title": "The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: A retrospective, multi-centric cohort study", "author": "Salehi", "doi-asserted-by": "crossref", "first-page": "18", "journal-title": "Eur. J. Med. Res.", "key": "ref_28", "volume": "27", "year": "2022" }, { "DOI": "10.1001/jama.2021.23866", "article-title": "Antiplatelet Therapy in Patients With COVID-19-More Is Less?", "author": "Spaetgens", "doi-asserted-by": "crossref", "first-page": "223", "journal-title": "JAMA", "key": "ref_29", "volume": "327", "year": "2022" }, { "DOI": "10.3390/jcm12052038", "doi-asserted-by": "crossref", "key": "ref_30", "unstructured": "Bolek, T., Samos, M., Jurica, J., Stanciakova, L., Pec, M.J., Skornova, I., Galajda, P., Stasko, J., Mokan, M., and Kubisz, P. (2023). COVID-19 and the Response to Antiplatelet Therapy. J. Clin. Med., 12." }, { "article-title": "The first Chinese oral anti-COVID-19 drug Azvudine launched", "author": "Yu", "first-page": "100321", "journal-title": "Innovation", "key": "ref_31", "volume": "3", "year": "2022" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/2076-2607/11/7/1859" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Virology", "Microbiology (medical)", "Microbiology" ], "subtitle": [], "title": "Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China", "type": "journal-article", "volume": "11" }